New Imaging Agent Detects Rare Neuroendocrine Tumors
By MedImaging International staff writers Posted on 23 Jun 2016 |
Image: Neuroendocrine tumor cells (Photo courtesy of MedScape).
A novel radioactive probe will help locate tumors in adult and pediatric patients suffering from somatostatin receptor positive neuroendocrine tumors (NETs).
Netspot, a product of Advanced Accelerator Applications (AAA; Saint-Genis-Pouilly, France), is a sterile, single-dose kit for the preparation of Ga 68 dotatate injection, a radioactive diagnostic agent used in positron emission tomography (PET) imaging. The imaging agent functions as an analogue of somatostatin, with uptake of the dotatate reflecting levels of somatostatin receptor density in NETs. As Netspot contributes to the overall long-term cumulative radiation exposure, patients should drink and urinate as often as possible during the first hours following administration to help reduce risk.
“Use of advanced imaging techniques to detect rare neuroendocrine tumors at an early stage in patients is critical,” said Libero Marzella, MD, PhD, director of the division of medical imaging products at the U.S. Food and Drug Administration (FDA, Silver Spring, MD, USA) Center for Drug Evaluation and Research (CDER). “Netspot provides another diagnostic tool whose results will help clinicians determine the location and extent of the tumor. This information is important for planning the appropriate course of therapy.”
“The FDA approval of Netspot is a key milestone in our mission of improving the lives of NET patients,” said Stefano Buono, CEO of AAA. “NETSPOT has the potential to significantly improve the accuracy of NET diagnosis, while reducing radiation exposure for patients. We believe that the use of Netspot should also offer increased comfort for patients by potentially shortening a procedure that is currently performed over 24 hours or more to just a few hours.”
NETs are rare benign or malignant tumors that develop in the hormone-producing cells of the body’s neuroendocrine system. These cells are found throughout the body in distinct organs, such as the stomach, intestines, pancreas, lungs, and other locations. NETs have receptors for somatostatin, a hormone that regulates the endocrine system. The estimated incidence of NETs for the combined populations of the United States and the European Union is approximately 47,300 patients per year.
Related Links:
Advanced Accelerator Applications
U.S. Food and Drug Administration
Netspot, a product of Advanced Accelerator Applications (AAA; Saint-Genis-Pouilly, France), is a sterile, single-dose kit for the preparation of Ga 68 dotatate injection, a radioactive diagnostic agent used in positron emission tomography (PET) imaging. The imaging agent functions as an analogue of somatostatin, with uptake of the dotatate reflecting levels of somatostatin receptor density in NETs. As Netspot contributes to the overall long-term cumulative radiation exposure, patients should drink and urinate as often as possible during the first hours following administration to help reduce risk.
“Use of advanced imaging techniques to detect rare neuroendocrine tumors at an early stage in patients is critical,” said Libero Marzella, MD, PhD, director of the division of medical imaging products at the U.S. Food and Drug Administration (FDA, Silver Spring, MD, USA) Center for Drug Evaluation and Research (CDER). “Netspot provides another diagnostic tool whose results will help clinicians determine the location and extent of the tumor. This information is important for planning the appropriate course of therapy.”
“The FDA approval of Netspot is a key milestone in our mission of improving the lives of NET patients,” said Stefano Buono, CEO of AAA. “NETSPOT has the potential to significantly improve the accuracy of NET diagnosis, while reducing radiation exposure for patients. We believe that the use of Netspot should also offer increased comfort for patients by potentially shortening a procedure that is currently performed over 24 hours or more to just a few hours.”
NETs are rare benign or malignant tumors that develop in the hormone-producing cells of the body’s neuroendocrine system. These cells are found throughout the body in distinct organs, such as the stomach, intestines, pancreas, lungs, and other locations. NETs have receptors for somatostatin, a hormone that regulates the endocrine system. The estimated incidence of NETs for the combined populations of the United States and the European Union is approximately 47,300 patients per year.
Related Links:
Advanced Accelerator Applications
U.S. Food and Drug Administration
Latest Radiography News
- Novel Breast Imaging System Proves As Effective As Mammography
- AI Assistance Improves Breast-Cancer Screening by Reducing False Positives
- AI Could Boost Clinical Adoption of Chest DDR
- 3D Mammography Almost Halves Breast Cancer Incidence between Two Screening Tests
- AI Model Predicts 5-Year Breast Cancer Risk from Mammograms
- Deep Learning Framework Detects Fractures in X-Ray Images With 99% Accuracy
- Direct AI-Based Medical X-Ray Imaging System a Paradigm-Shift from Conventional DR and CT
- Chest X-Ray AI Solution Automatically Identifies, Categorizes and Highlights Suspicious Areas
- AI Diagnoses Wrist Fractures As Well As Radiologists
- Annual Mammography Beginning At 40 Cuts Breast Cancer Mortality By 42%
- 3D Human GPS Powered By Light Paves Way for Radiation-Free Minimally-Invasive Surgery
- Novel AI Technology to Revolutionize Cancer Detection in Dense Breasts
- AI Solution Provides Radiologists with 'Second Pair' Of Eyes to Detect Breast Cancers
- AI Helps General Radiologists Achieve Specialist-Level Performance in Interpreting Mammograms
- Novel Imaging Technique Could Transform Breast Cancer Detection
- Computer Program Combines AI and Heat-Imaging Technology for Early Breast Cancer Detection